WallStSmart

Foghorn Therapeutics Inc (FHTX)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Foghorn Therapeutics Inc generates 3704% more annual revenue ($28.22M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -266.9%. RVMD earns a higher WallStSmart Score of 24/100 (F).

FHTX

Avoid

19

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.0Quality: 6.0
Piotroski: 2/9Altman Z: -5.05

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FHTX1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.5510/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

FHTX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$219.00M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-470.4%2/10

ROE of -470.4% — below average capital efficiency

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : FHTX

The strongest argument for FHTX centers on Debt/Equity.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : FHTX

The primary concerns for FHTX are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

FHTX profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.

FHTX carries more volatility with a beta of 2.89 — expect wider price swings.

FHTX is growing revenue faster at -45.1% — sustainability is the question.

FHTX generates stronger free cash flow (-25M), providing more financial flexibility.

Bottom Line

RVMD scores higher overall (24/100 vs 19/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Foghorn Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?